Intrahospital flu vaccine for adults with high cardiovascular risk when admitted for ACS or heart failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults admitted for acute coronary syndrome or congestive heart failure are randomized to receive either an intrahospital influenza vaccination offer plus standardized counseling or counseling plus a discharge vaccine recommendation. The primary outcome is vaccination rate by the end of the influenza season. The intervention aligns with German STIKO recommendations and compares in-hospital vaccination to standard outpatient vaccination guidance. Safety, feasibility, and uptake are assessed within the index hospitalization period. The trial is conducted at two German centers and involves collaboration between an academic hospital and industry sponsor.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older
* Hospitalized due to acute coronary syndrome (ACS) or congestive heart failure (CHF) and fulfilling the criteria for influenza vaccination according to the recommendations of the German Standing Vaccination Committee (STIKO)
* Written informed consent

Exclusion Criteria:

* Already received seasonal influenza vaccination in the current season, based on self-reported vaccination status and/or vaccination certificate
* Laboratory-confirmed active influenza infection during the index hospitalization
* Contraindication for vaccination (e.g., known allergy)
* Inability to provide written informed consent

Where it's running

• Clinic III for Internal Medicine, University Hospital of Cologne
  Cologne, Germany Recruiting
• Department of Cardiology, University Heart and Vascular Centre Hamburg
  Hamburg, Germany Recruiting

Study contacts

• Principal investigator: Stephan Baldus, Prof. Dr. med. — Clinic III for Internal Medicine, University Hospital of Cologne
• Study coordinator: Sebastian Heyne, Dr. med.
• Email: sebastian.heyne@uk-koeln.de
• Phone: +49 221 478-82019

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Common femoral vein-to-artery diameter ratio to detect elevated LVEDP

  Researchers test whether the ratio of the common femoral vein to artery diameters, measured by ultrasound, can flag elevated LV end-diastolic pressure in patients having coronary angiography.

  Recruiting Burapha University · Chon Buri · NCT07866859

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Dapagliflozin to Improve Exercise and Heart Function in Fontan Patients

  This study tests whether the diabetes drug dapagliflozin can improve exercise capacity and heart function in people who had a Fontan procedure.

  Recruiting Phase 4 The University of Hong Kong · Hong Kong and 1 other locations · NCT07482943

• Vicadrostat versus spironolactone: effects on kidney function and protein markers

  This will test whether vicadrostat or spironolactone, each given with empagliflozin, changes kidney function and blood/urine protein patterns in adults with CKD and heart disease or heart failure.

  Recruiting at 2 sites Phase 2 University Medical Center Groningen · Groningen, Provincie Groningen and 1 other locations · NCT07304817

• Freesolve resorbable magnesium scaffold vs. Xience stent for up to two new heart artery lesions

  This trial tests whether the Freesolve resorbable magnesium scaffold works as well as the Xience drug-eluting stent for treating up to two new coronary artery lesions in adults.

  Recruiting at 3 sites Teleflex · Washington D.C., District of Columbia and 2 other locations · NCT07258290

• Pulmonary Artery Denervation for a specific type of heart and lung pressure problem

  This study tests whether the Enhancor System can safely and effectively help patients with combined pre- and post-capillary pulmonary hypertension due to left heart disease when added to standard therapy.

  Recruiting at 18 sites Pulnovo Medical, Inc. · Tucson, Arizona and 18 other locations · NCT07214376

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.